Brief: GT Biopharma Provides Enrollment Update On GTB-3650 Phase 1 Trial In Patients With Relapsed Or Refractory (R/R)CD33 Expressing Hematologic Malignancies
08/10/2025 14:18
Oct 8 (Reuters) - GT Biopharma Inc GTBP.O: GT BIOPHARMA PROVIDES ENROLLMENT UPDATE ON GTB-3650 PHASE 1 TRIAL IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD33 EXPRESSING HEMATOLOGIC MALIGNANCIES Source text: ID:nGNX9Wjd1q Further company coverage: GTBP.O ((Reuters.Briefs@thomsonreuters.com;))